Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results ...
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...
The position in Novo Nordisk hindered returns as the company’s Wegovy obesity treatment missed revenue expectations due to a ...
The agency is also evaluating Novo Nordisk’s (NVO) semaglutide drugs for the same label. After significant pushback, the FDA ...
GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...
Investor's Business Daily on MSN17h
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity ShotAmgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...
While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...
Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...
If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback